What is the efficacy and safety of apixaban compared to warfarin for patients with atrial fibrillation and a history of cancer?
The ARISTOTLE trial found that apixaban was both efficacious and safe in patients with atrial fibrillation and a history of cancer. The study showed that apixaban was associated with a lower risk of major bleeding and stroke compared to warfarin. Additionally, a network meta-analysis of oral anticoagulants in atrial fibrillation patients with cancer found similar results, with apixaban being associated with a lower risk of major bleeding and stroke compared to warfarin. Thus, apixaban appears to be an effective and safe alternative to warfarin for patients with atrial fibrillation and a history of cancer.